OU, DA LIANG,欧大谅,歐大諒,SHIAU, CHUNG WAI,萧崇玮,蕭崇瑋,HSU, CHIUN,许骏,許駿
申请号：
TW102141507
公开号：
TW201423102A
申请日:
2013.11.14
申请国别(地区):
TW
年份:
2014
代理人:
摘要：
The present application provides a method for screening compounds for cancer treatment comprising treating cancer cells with a candidate compound for sufficient time for detectable expression of a gene selected from GADD45 family； and detecting the level of expression of the gene as compared to the level of expression in the absence of the candidate compound； wherein an increased level of expression in the presence of the candidate compound as compared to expression in the absence of the candidate compound indicates that the candidate compound acts as an inhibitor of the cancer cells. In some embodiments, the method can be used for screening compounds for treatment of sorafenib-resistant hepatocellular carcinoma. The present application further provides a method for treating hepatocellular carcinoma comprising administering to a subject having hepatocellular carcinoma a therapeutic effective amount of an agonist of GADD45 family.本發明係提供一種篩選癌症治療之化合物之方法，包括：以一候選化合物處理癌細胞一段時間，該時間足以使選自GADD45家族之基因達到可檢測表現；及檢測該基因之表現程度，與缺乏該候選化合物之表現程度相比較；其中，與缺乏該候選化合物之表現程度相比較，該候選化合物存在之表現程度增加時，係指示該候選化合物作為該癌細胞抑制劑之作用。於一些實施案例中，該方法可用於篩選治療抗蕾莎瓦肝細胞癌之化合物。本發明進一步提供一種治療肝細胞癌之方法，包括對具有肝細胞癌之標的物投予一治療有效量之GADD45家族之促效劑。
